Alnylam Offering Value-Based Deals In EU For Breakthrough RNAi Drug Onpattro

 
• By Sten Stovall

Alnylam's president tells Scrip the RNAi pioneer is offering outcomes-based contracts for its first ever product to payers in the European Union following Onpattro's approval there in August. He also says payers "must pay for innovation."

Value-Cost
Alnylam offering value- or outcomes-based Onpattro contracts linked to improvements. • Source: Shutterstock

More from Strategy

More from Business